Prescribing pattern of drugs in stroke patients: A prospective study

Mohammad Yaseen Abbasi, Md Avez Ali
Department of Pharmacy Practice, St. Peter’s Institute of Pharmaceutical Sciences, Vidyanagar, Hanamkonda, Warangal, Andhra Pradesh, India,

ABSTRACT

Objectives: The population-based estimates confirm a rising trend in both incidence and prevalence of stroke in India. The main objective is to assess the prescribing pattern of drugs in hospitalized stroke patients.

Materials and Methods: A Prospective observational study was carried out for a period of 6 months in the inpatient department. The inclusion criteria of the present study are patients of either sex aged ≥ 18 years, patients who were diagnosed as a stroke patient, and admitted in the intensive care unit of the hospital.

Results: A total of 102 prescriptions were analyzed during the 6-month study period. This was found to be higher in men 68 (33.33%). A total of 69 (67.64%) were having habits of smoking and alcohol consumption. In the study of 102 patients, 69 (32%) were identified as ischemic stroke patients and 33 (32%) suffered hemorrhagic stroke. The major co-morbidities identified were hypertension and diabetes mellitus, which were seen in 34 (33.33%) and 18 (17.64%), respectively. Among the 102 patients, 77 (75.49%) were administered cerebral activators. In this study of prescriptions of drugs in stroke, majority of the patients were treated with neurotonics drugs. Among the 102 patients, 85 (83.33%) were administered neurotonics drugs. In this study, we observed that the most popular antiplatelet was clopidogrel, which was prescribed to 48 (47.05%). In anticoagulants, only enoxapain was used in our hospital for stroke patients. This medication was administered to 27 (26.47%) patients.

Conclusion: The prescribing pattern of drugs should be based on severity of stroke, associated co-morbid conditions, and currently available evidences in order to promote the quality use of drugs.

Key words: Drugs, prescribing pattern, prospective study, stroke

INTRODUCTION

Stroke is a major cause of mortality worldwide and commonly occurs in elderly patients. Indian population is relatively young compared with the Western countries but India has already attained epidemic proportions of annual incidence of stroke 145/100,000 per year during 2003–06. Stroke mortality rate in India is 22 times that of malaria and 1.4 times that of tuberculosis. There are certain risk factors that are rare but known to occur among Indians (like hypertension and diabetes). The common risk factors are diabetes, hypertension, smoking, and obesity. The population-based estimates confirm a rising trend in both incidence and prevalence of stroke in India. The prophylaxis drugs has remained an important drug for hypertensive and diabetes mellitus patients to avoid any stroke in future.

The physicians are often making the decision as to which agent to choose in a patient-by-patient basis. In the present study, we sought to look at the
prescribing patterns of neurologists and physicians to identify the choice of a specific agent over another and what changes are made when a stroke occurs in these patients. Other than risk factor management, antithrombotic agents have a well-established and important role in secondary prevention of ischemic stroke. By 2025, four out of five stroke events will occur in people living in India. The prevalence of stroke in India varies in different regions of the country and, ranges from 40 to 270 for every 100,000 population. Approximately 12% of all strokes occur in the population < 40 years of age. Major risk factors identified in India are hypertension (blood pressure > 95 mmHg diastolic), hyperglycemia, tobacco use, and low hemoglobin levels. In this study, we concentrate on the use of different kind of drugs to treat the sign and symptoms of stroke.

The drug treatment strategy also involved with selecting drugs like thrombolytics anticoagulants, antihypertensives (angiotensin converting enzyme-inhibitors, angiotensin II receptor blockers, and diuretics), blood lipid lowering agents (statins), antiplatelet drugs (aspirin and clopidogrel), and cerebral activators. It is also recommended to select a route, and dosage form of drugs to have optimal therapeutic effects to manage Cerebrovascular Accident.\textsuperscript{[7,8]}

**MATERIALS AND METHODS**

This study was carried out at Super-specialty Hospital, located at the heart of the city of Warangal. This hospital has a 300-bed facility along with all advanced instruments.

**Study design**

The design of study type was prospective cross sectional among 102 in-patients who were diagnosed as stroke.

**Data collection**

A data collection form was designed to collect patients data including patients personal details (name, age, and sex) family history and past medical history, complications and lifestyle medication, laboratory data, therapeutic management, drug data (brand and generic name of all drugs prescribed to treat stroke, dose frequency, route of administration, and dose of drugs), and discharge summary. The required information was collected from the case sheets of individual patients in the designed data collection form. The patients were interviewed to collect all the relevant data regarding patient care. The patient selection criterion was depending upon fulfillment of inclusion criteria. The informed consent/permission was taken from patient or from his/her attenders. All the necessary information was provided to them about this study. The collected data was transferred to the Excel Sheet software of Microsoft Office. This data was categorized and tables were prepared. As per need, various calculations were done to find out standard mean deviations and percentages. All mandatory ethical issues were discussed and carried out according to the permission granted by the ethical committee of the Hospital.

**Inclusion criteria**

- Patients of either sex aged ≥ 18 years.
- Patients who were diagnosed as a stroke patient and admitted in intensive care unit of hospital.

**Duration of study and analysis**

This study was carried out in the intensive medical care department of the hospital. This study period was for 6 months from January to June 2011 and analysis of data was done in the month of August 2011.

**RESULTS**

In the study, it was found that, a total of 102 patients were admitted to the ward during the study period. Of the total admissions, 68 (33.33%) and 34 (66.66%) patients were male and female, respectively [Table 1]. Out of the 102 patients, 69 (67.64%) were having habits of smoking and alcohol consumption [Table 2]. In this study of 102 patients, 69 (32%) were identified as ischemic stroke patients and 33 (32%) suffered hemorrhagic stroke Blood pressure was high in 73 (71.56%) at the time of admission to the

| Group (years) | Male (N=102 (%)) | Female (N=102 (%)) |
|---------------|------------------|--------------------|
| 25-40         | 5 (7.35)         | 4 (11.76)          |
| 41-55         | 24 (35.29)       | 9 (26.47)          |
| 56-70         | 28 (41.17)       | 15 (44.11)         |
| ≥ 71          | 11 (16.07)       | 6 (17.64)          |
| Mean±SD       | 59±12.022        | 58.9±12.032        |

| Characteristics | Male (N=102) | Female (N=102) |
|-----------------|-------------|---------------|
| Smoking (28)    | 22 (21.56)  | 6 (5.88)      |
| Alcoholics (39) | 39 (38.23)  | 2 (1.96)      |
| Ischemic stroke (69) | 48 (47.05) | 21 (20.58)    |
| Hemorrhagic stroke (33) | 20 (19.60) | 20 (19.60)    |
hospital. The major co-morbidities identified were hypertension and diabetes mellitus, which were seen in 34 (33.33%) and 18 (17.64%), respectively, among the stroke patients [Table 3]. Among stroke complication, right and left hemiplegia 50 (49.01%) were attacked equally in population but right hemiplegia produced aphasia in 52 (50.98%) and blurred vision in 3 (2.94%). Among the 102 patients of stroke, 77 (75.49%) were administered cerebral activators. In this study, patients with hypertension were treated with different classes of antihypertensive. These kinds of drugs are less prescribed; Ramipril was prescribed to 3 (2.94%) patients. In this study, stroke patients also suffered seizures, hence Phenytoin was prescribed to 24 (23.52%) patients. Out of the 102 stroke patients, Mannitol was administered to reduce intracranial edema and this was prescribed to 100 (98.03%) patients. In this 102 stroke patients study, Dyslipidimics was administered to 22 (21.56%) patients. In this study of prescriptions of drugs in stroke, majority of the people were treated with neurotonics drugs. Among the 102 patients, 85 (83.33%) were administered neurotonics drugs. In this study, we observed that the most popular antiplatelet was clopidogrel, which was prescribed to 48 (47.05%) patients. In anticoagulants, only Enoxaprain was used in our hospital for stroke patients. This medication was given to 27 (26.47%) patients [Table 4].

**DISCUSSION**

Males are very susceptible to stroke compared with females, this may be due to risk factors and habits. It showed in this study, the numbers of male patients were comparatively more than the numbers of female patients. One survey reported that male to female ratio of stroke to be 1.7. Another study done in Taiwan by Wu et al., revealed that 736 and 425 were male and female, respectively. Similarly, one study done in Turkey by Nuray and Mehtap, estimated 40 (57.14%) males and 28 (40%) females. Similar findings correlates with the study at Pondicherry, where 39 (60.93%) and 25 (39.06%) were males and females, respectively. The mean age of the patients in this study was 58.98 ± 12.27 years. In the present study, we found similar results as reported by Po et al. in Taiwan.

Most of the patients who were victim of stroke come under the age group of 56–70 years. This study also gives uniform result as shown by previous study, which found that age was the risk factor for stroke and it enhances the probability of stroke even more; this study was carried out by Wu in 2011, which showed that the age group of 50–75 years suffered optimum of 702 (60.5%) patients. It was also studied that the mean age of stroke patients were 55.5(Male) year and 57.9 (Female) years. Nuray and Mehtap

---

**Table 3: Co-morbid and stroke complication**

| Co-morbid disease          | Numbers N=102 (%) |
|----------------------------|--------------------|
| Hypertension               | 64 (62.74)         |
| Diabetes mellitus          | 26 (25.49)         |
| Old stroke                 | 9 (8.82)           |
| Coronary artery disease    | 3 (2.94)           |
| Right hemiplegia           | 50 (49.01)         |
| Left hemiplegia            | 50 (49.01)         |
| Bilateral hemiplegia       | 2 (1.96)           |
| Aphasia                    | 52 (50.98)         |
| Blurred vision             | 3 (2.94)           |

**Table 4: Drugs prescribed in stroke patients**

| Drugs category                      | Number N=102(%) |
|-------------------------------------|-----------------|
| Anticoagulant drugs                 |                 |
| Enoxaprain                          | 44 (43.13)      |
| Cerebral activator drugs            |                 |
| Piracetam                           | 49 (48.03)      |
| Nimodipine                          | 10 (9.8)        |
| Piracetam+Nimodipine                | 18 (17.64)      |
| Beta blockers                       |                 |
| Metoprolol                          | 7 (6.86)        |
| Atenolol                            | 4 (3.92)        |
| Calcium channel blockers            |                 |
| Amlodipine                          | 26 (25.49)      |
| Nifedipine                          | 22 (21.55)      |
| ACE Inhibitors                      |                 |
| Ramipril                            | 3 (2.94)        |
| Angiotensin antagonist              |                 |
| Olmisertan                          | 3 (2.94)        |
| Telmisertan                         | 3 (2.94)        |
| Antihypertensive combination therapy|                 |
| Amlodipine+Atenolol                 | 9 (8.82)        |
| Telmisertan+Hydrochlorothiazides    | 11 (10.78)      |
| Antiepileptic drugs                 |                 |
| Phenytoin                           | 24 (23.52)      |
| Dyslipidimic drugs                  |                 |
| Atorvastatin                        | 20 (19.6)       |
| Rosuvastatin                        | 2 (1.96)        |
| Neurotonics drugs                   |                 |
| Citicholine                         | 36 (35.29)      |
| Mecobalamin                         | 5 (4.9)         |
| Multivitamins                       | 44 (33.33)      |
| Citicholine+Multivitamins           | 5 (4.9)         |
| Citicholine+Mecobalamin             | 5 (4.9)         |
| Antiplatelet drugs                  |                 |
| Aspirin                             | 2 (1.96)        |
| Clopidogrel                         | 48 (47.05)      |
| Aspirin+Clopidogrel                 | 44 (43.13)      |
also reported similar results that the age group of 61–71 years were more prone to stroke and there were an estimated 28 (40%) patients in the study.[11] In this study, it was shown that 36 (35.29%) were of stage II hypertension. Nagaraj et al. from Chennai also reported similar results, they observed hypertension in 115 (46%) patients with stroke.[14] A study conducted by Meschia et al., also reported that 359 (71%) patients were having hypertension.[13] This result also co-relates with the study of Guo et al., who reported 69 (65.7%) hospitalized stroke patients having hypertension.[15]

In our research, it has been found that 28 (27.45%) patients were smokers and 41 (40.19%) patients consumed alcohol. An Indian-based study by Sharma and Sharma reported that 31.2% smokers were at risk of stroke.[14] Kim et al. reported that 367 (32.4%) patients were having habit of smoking.[13] Sacco et al. categorized risk for recurrent stroke as 285 out of 3013 were moderate alcoholic.[17] Wu reported that cigarette and alcohol consumption account to stroke by 57.7% and 30.8%, respectively.[19] Among the 102 patients of stroke in this study, 69 (32%) were identified as ischemic stroke patients and 33 (32%) suffered hemorrhagic strokes. Bharucha and Kuruvilla in Mumbai recorded a larger number of ischemic to hemorrhagic strokes as 57.3–89.7% and 13.6–37.9%, respectively, in Western countries.

This study also gives uniform result as the study by Nuray and Mehtap in Turkey. It was reported that ischemic stroke is the major type suffered in Turkey, ischemic stroke 52 (74.28%) and hemorrhagic stroke 18 (25.71%), respectively.[11] Kalita et al. concluded that ischemic patients were more in number compared with hemorrhage stroke.[18] Nandigam et al. also reported 44 (68.75%) and 20 (31.25%) patients of ischemic and hemorrhagic, respectively.[12] All stroke patients showed stroke-related complications; 50 (49.01%) with right hemiplegia, 50 (49.01%) with left hemiplegia, 2 (1.96%) with both side hemiplegia, 52 (50.98%) suffered from Aphasias and 3 (2.94%) suffered of blurred vision. A study by Kenneth and Cheng reported the prevalence of stroke complications as 69% hemiparesis, 61% leg paresis, 57% Aphasias, and 51% vision-related problems.[19] Nuray and Mehtap from Turkey reported that stroke complication among patients as 30 (42.85%) left hemiparesis and 40 (57.14%) right hemiparesis.[11] Gall reported that 63 (35.6%) patients suffered from visual field defect due to stroke.[20] The major co-morbidities were identified as hypertension and diabetics mellitus, which were seen in 34 (33.33%) and 18 (17.64%) among the stroke patients. Wu et al. reported about co-morbidities of stroke; hypertension was identified in 65.2% male and 68.2% female, respectively. Likewise for diabetes, 29.9% male and 34.4% female, respectively.[14]

A study reported by Meschia et al., found 71% and 27% patients having past history of hypertension and diabetes mellitus, respectively. Guo et al. reported in their study about past medical history of patients having 65.7% of hypertension and 43.8% of diabetes.[21] Hypertension was the major co-morbidity of stroke patients and it was estimated to be 82.4% as reported by Helen et al.[22] In the present study, we found that 77 (75.49%) patients were administered cerebral activators. The preferred cerebral activator was Piracetam, which was administered to 49 (48.03%) stroke patients, this was followed by Nimodipine 10 (9.8%), and few patients were simultaneously co-administered both, Piracetam and Nimodipine 18 (17.64%).

Similarly, Ricci et al. reported that Piracetam has neuroprotective and antithrombotic effects that may help to reduce death and disability in people with acute stroke. Eleven (10.78%) patients were prescribed for beta blocker drugs for management of hypertension and hemorrhagic conditions. Metoprolol was prescribed for 7 (6.86%) patients and Atenolol 50 mg was administered to 4 (3.92%) stroke patients.

In all category of antihypertensive calcium channel blockers were used in majority of 48 (47.05%) prescriptions. Amlodipine was prescribed with preference as 26 (25.49%), the next drug in this category was Nifedipine, which was prescribed to 22 (21.65%) patients. The angiotensin converting enzyme inhibitors (ACE inhibitors) drugs were less prescribed, Ramipril was prescribed to 3 (2.94%) patients. Among angiotension receptor blockers (ARB’s), Olmisertan were administered to 3 (2.94%) patients and Telmisertan were administered to 3 (2.94%) patients. Twenty (19.6%) patients were administered fixed dose combination therapy. The combination of Amlodipine and Atenolol was administered to 9 (8.825%) patients, whereas Telmisertan and hydrochlorothiazide combination was administered to 11 (10.78%) patients. Eva et al. also reported that 7843 patients were prescribed by ACE inhibitors and angiotensin antagonist, 9023 and 4459 patients were prescribed by beta blockers and calcium channel inhibitors, respectively.[23] Phenytoin was prescribed to 24 (23.52%) patients, Phenytoin was used as prophylaxis. In the study by Silverman, he reported that 17.6% patients were prescribed Phenytoin.[24]
CONCLUSION

The complete study shows that the uses of medication in stroke are cerebral activators as Piracetam and Nimodipine. Various antihypertensives were used, as Calcium Channel Blockers, Beta Blockers, ACE Inhibitors, Angiotensin Antagonists, and various Combinations. Some stroke patients were also prescribed Antiepileptic as Phenytoin. Most of the patients were administered Mannitol to reduce intracranial edema. In this study, various patients were administered Atorvastatins as Dyslipidimics to reduce higher cholesterol. Aspirin and Clopidogrel were only used as Antiplatelete. The drug Enoxapain is only used as Anticoagulant. The obtained data is only specific to the site of study. But the usage of drugs in stroke may be different at different Indian Hospitals, due to physician’s choice and preferences. This study initiating that, there should be a Standard Stroke Pharmacotherapy guidelines in India and this may be possible in future.

ACKNOWLEDGMENT

The authors gratefully acknowledge Dr. J. Sudhakar Reddy, Superintendent of Rohini Super Specialty hospital, Warangal, for his consecutive support and suggestions during data collecting from the hospital.

REFERENCES

1. Koda Kimble MA, Young LY, Aldredge BK, Corelli RL, Guglielmo BJ, Kradjan WA, and Williams BR. Cerebrovascular disorders. In: Koda-Kimble MA, editor. Applied therapeutics: The clinical use of drugs. 9th ed. New York: Lippincott Williams and Wilkins; 2009. p. 205-74.
2. Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: Estimates from monitoring, surveillance, and modeling. Lancet Neurol 2009;8:345-54.
3. Banerjee TK, Roy MK, Bhoi KK. Is stroke increasing in India-preventive measures that need to be implemented? J Indian Med Assoc 2005;103:162-6.
4. Census of India, Registrar General and Census Commissioner, Delhi, India: 2001.
5. Banerjee TK, Das K. Epidemiology of stroke in India. Neurol J Southeast Asia 1998;3:5-8.
6. Abraham J, Rao PS, Inbaraj SG, Shetty G, Jose CJ. An epidemiological study of hemiplegia due to stroke in South India. Stroke 1970;1:477-81.
7. Das SK, Banerjee TK, Biswas A, Roy T, Raut DK, Mukherjee CS, et al. A prospective community-based study of stroke in Kolkata, India. Stroke 2007;38:906-10.
8. Dalal PM, Malik S, Bhattacharjee M, Trivedi ND, Vairale J, Bhat P, et al. Population-based stroke survey in Mumbai, India: Incidence and 28-day case fatality. Neuroepidemiology 2008;31:254‑61.
9. Kaul S. Stroke in India: We different from the world. Pak J Neurol Sci 2007;2:158-64.
10. Wu CY, Wu HM, Lee JD, Weng HH. Stroke risk factors and subtype in different age group: A hospital-based study. Neurol India 2010;58:863-8.
11. Nuring D, Mehtap T. Quality of life in stroke patients. Neurol India 2010;58:697-701.
12. Nandigam K, Narayan SK, Elangovan S, Dutta TK, Sethuraman KR, Das AK. Feasibility of acute thrombolytic therapy for stroke. Neurol India 2003;5:470-3.
13. Kim WJ, Ko Y, Yang MH, Im SH, Park JH, Lee J, et al. Differential effect of previous antiplatelet use on stroke severity according to stroke mechanism. Stroke 2010;41:1200-4.
14. Nagaraj D, Panda S, Ravi VT. Clinical epidemiology of stroke. Annal Ind Acad Neurol 2005;8:85-93.
15. Meschia JF, Case LD, Worrall BB, Brown RD Jr, Brott TG, Frankel M, et al. Family history of stroke and severity of neurologic deficit after stroke. Neurology 2006;67:1396-402.
16. Sharma SR, Sharma N. hyper acute thrombolysis with
recombinant tissue plasminogen activator of acute ischemic stroke: Feasibility and affectivity from an Indian perspective. Ann Indian Acad Neurol 2008;13:221-4.

17. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Aspirin and extended release Dipyridamole versus Clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238-51.

18. Kalita J, Misra K, Ranjan P. Prescribing pattern of antiedema therapy in stroke by neurologic and general physicians. Neurol India 2004;52:191-3.

19. Yew KS, Cheng E. Acute Stroke Diagnosis. Fam Physician 2009;80:33.

20. Gall CO, Franke GH, Sabel BA. Vision related quality of life in first stroke patients with homonymous visual field defects. Health Qual Life Outcomes 2010;8:33.

21. Guo Y, Wu Q, Zhang L, Yang T, Zhu P, Gao W, et al. Antithrombotic therapy in very elderly patients with atrial fibrillation: Is it enough to assess thromboembolic risk? Clin Interv Aging 2010;5:157-62.

22. Helen LP, Lin YJ, Hseuh H. The prescribing patterns of antithrombotic agents for prevention of recurrent ischemic stroke. Acta Neurol Taiwan 2009;18:98-103.

23. Glader EL, Sjölander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the First 2 years after stroke. Stroke 2006;41:397-401.

24. Silverman IE. Post stroke Seizures. Arch Neurol 2002;59:194-202.
